Survey

Last month's survey results:

How does your health system handle new drug approvals?

We have a 6-month moratorium on newly FDA-approved drugs: 23%

We have a 12-month moratorium on newly FDA-approved drugs: 9%

If approved by the P&T committee, newly FDA-approved drugs can be added at anytime without restrictions: 41%

If approved by the P&T committee, newly FDA-approved drugs can be added at anytime with step therapy or other modality to manage drug use and cost: 18%

Other: 9%

This month we would like to know...

Do you support The Preserving Access to Life-Saving Medicines Act, which would increase FDA's authority to prevent prescription drug shortages?

• Yes

• No

Digital Edition

ACP issues guideline for intensive insulin therapy in hospitalized patients

The American College of Physicians (ACP) recently issued 3 recommendations for use of intensive insulin therapy for the management of glycemic control in hospitalized patients. Read full article.

US Marshals seize Auralgan Otic Solution

In mid February, US Marshals acting on a request of FDA seized all lots of Auralgan Otic Solution from Integrated Commercialization Solutions (ICS) in Brooks, Ky. Read full article.

FDA approves azilsartan medoxomil to treat hypertension

FDA approved azilsartan medoxomil tablets (Edarbi, Takeda Pharmaceuticals North America) to treat hypertension in adults. Read full article.

FDA approves guanfacine ER tablets to treat ADHD in children, teens

FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program. Read full article.

FDA approves roflumilast for severe COPD

FDA approved the first-and-only selective phosphodiesterase type 4 inhibitor roflumilast (Daliresp, Forest Pharmaceuticals), once-daily oral tablet to decrease the frequency of exacerbations or worsening of symptoms from severe chronic obstructive pulmonary disease. Read full article.

Company expands generic warfarin recall to other product lines

A recent recall of generic warfarin tablets was expanded to include 6 other drug products prepared on the same packaging line. Read full article.

Corticosteroids' safety affirmed in treatment of childhood asthma

Children being treated with a short course of oral corticosteroids for an acute asthma attack may experience a brief and transient depression of their immune response, according to a recent study conducted by Université de Montréal. Read full article.

Contact Us

Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.

Survey

Top 5 Web Stories

Contact Us